Yasutaka Yamada

32PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsGenome structure and regulationMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Aug 15, 2026
Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

|Mar 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

Koichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada

|Mar 05, 2026
Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression.

Arianna Brevi, Marco Lorenzoni, Sara Caputo

|Feb 09, 2026
Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial.

Yasutaka Yamada

|Nov 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.

Tomoki Shirafuji, Yasutaka Yamada, Kodai Sato

|Oct 23, 2025
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.

Sheng-Yu Ku, Nishat Manzar, Maria Mica Garcia

Pageof 6

Frequent Collaborators

8 joint publications

Shinichi Sakamoto

6 joint publications

Himisha Beltran

5 joint publications

Naohiko Seki

5 joint publications

Rii Junryo